|Mr. Herm Cukier||CEO & Director||655.05k||N/A||1966|
|Mr. Scott M. Plesha||Pres & Chief Commercial Officer||586.18k||N/A||1965|
|Mr. James Vollins J.D.||Gen. Counsel, Chief Compliance Officer & Corp. Sec.||77.08k||N/A||1969|
|Dr. Thomas B. Smith FAAFP, M.D.||Chief Medical Officer||217.86k||N/A||1961|
|Ms. Mary Theresa Coelho||CFO & Treasurer||N/A||N/A||1962|
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in opioid tolerant adult patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.
BioDelivery Sciences International, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 4; Compensation: 6.